• Approved Myeloma Drug in Limbo After Negative ODAC Review

    3 days ago - By MedPageToday

    The FDA's Oncologic Drugs Advisory Committee may have dealt a decisive blow to the dangling accelerated approval of melphalan flufenamide for multiple myeloma.
    By a decisive 14-2 margin, ODAC voted on Thursday...
    Read more ...